Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...
PMLiVE12d
Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn
The exclusive collaboration and licensing agreement will see the companies co-develop and co-commercialise the long-acting amylin analog as both a standalone therapy and as a fixed-dose combination ...
Wall Street Journal11d
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
The companies plan to create a treatment combining Roche’s GLP-1 asset, CT-388, with Zealand Pharma’s amylin analog.
Morningstar11d
Roche Agrees to Develop Weight-Loss Therapy With Zealand Pharma
Roche Holding agreed a collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment using its CT-388 medicine combined with Zealand Pharma's petrelintide. The Swiss ...
Morningstar12d
Roche: Collaboration With Zealand Adds Depth to Obesity Strategy
Why it matters: Roche entered the obesity landscape with the $2.7 billion acquisition of Carmot in early 2024, giving the firm access to development-stage candidates, including CT-388 and oral ...
Business Insider11d
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
The companies will co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and Europe. Zealand Pharma will receive ...
CT company’s iconic headquarters targeted for demolition. Time running out for effort to save it
In the face of unfolding plans for demolition and redevelopment for warehousing and distribution, preservationists fighting for the survival of iconic Connecticut headquarters.